Neurotoxicity of Drugs of Abuse
- 1st Edition, Volume 8 - September 15, 2022
- Latest edition
- Editors: Lucio G. Costa, Michael Aschner, William Slikker Jr.
- Language: English
Neurotoxicity of Drugs of Abuse, Volume Eight provides carefully crafted reviews on the disruptive impact of drugs of abuse on the central nervous system. The neurotoxi… Read more
Neurotoxicity of Drugs of Abuse, Volume Eight provides carefully crafted reviews on the disruptive impact of drugs of abuse on the central nervous system. The neurotoxicity potential of several agents including marijuana, fentanyl, and ketamine are carefully reviewed, and their short-term and chronic effects are categorized. Pharmacokinetic profiles as well as mechanisms of action for these and other drugs of abuse such as alcohol and nicotine are also evaluated. The implications of short and long-term abuse for agents such as PCP are also characterized. The reader will come away with a fuller understanding of the adverse effects of drugs of abuse on the nervous system.
- Describes in detail the characteristics of drugs of abuse that produce neurotoxicity
- Summarizes both the short and long-term adverse effects of drugs of abuse on the nervous system
- Describes potential mechanisms of action of centrally acting drugs of abuse
Basic researchers, clinicians, epidemiologists, regulators, drug developers, chemists
Preface
William Slikker, Jr.
1. Cannabinoids
G. Jean Harry
2. Converging mechanisms in ethanol neurotoxicity
Miriam Beatriz Virgolini and Ricardo Marcos Pautassi
3. Neurotoxicology of nicotine and tobacco
Edward D. Levin
4. The neurotoxic potential of opioids including fentanyl and fentanyl analogs
R. Daniel Mellon
5. Phencyclidine (PCP)-induced neurotoxicity and behavioral deficits
Cheng Wang, Shuliang Liu, Leah E. Latham, Fang Liu, Tucker A. Patterson and William Slikker Jr
6. The mysterious beauty of ketamine: benefits and risks
Donald R. Mattison, Abdallah Alami, Thomas J. Moore and G. Caleb Alexander
- Edition: 1
- Latest edition
- Volume: 8
- Published: September 15, 2022
- Language: English
LC
Lucio G. Costa
Dr. Lucio G. Costa is Professor of Toxicology at the University of Washington in Seattle, and of Pharmacology/Toxicology at the University of Parma Medical School. He received a doctorate in Pharmacology from the University of Milano in 1977, and was a postdoctoral fellow at the University of Texas at Houston. He is a member of several national and international professional organizations, a Fellow of the Academy of Toxicological Sciences, and a European Certified Toxicologist. He received various award for his scientific accomplishments, including the Achievement Award from the Society of Toxicology. He serves in various editorial capacities for several toxicology journals, and is an active manuscript and grant reviewer. Dr. Costa has been the member of dozens of panels and committees at the national and international level dealing with toxicology and risk assessment issues. He has chaired and/or organized symposia at scientific meetings in the United States and internationally. He has been teaching classes in the area of toxicology, neurotoxicology and pharmacology to graduate and medical students for 30 years. He keeps an active research program in the area of neurotoxicology.
Affiliations and expertise
Professor of Toxicology, University of Washington, Seattle, WA, USAMA
Michael Aschner
Dr. Michael Aschner is currently the Harold and Muriel Block Chair in Molecular Pharmacology at Albert Einstein College of Medicine where he is also a Professor in the Departments of Molecular Pharmacology, Neuroscience, and Pediatrics. He is a leading expert in neurotoxicology and neurodevelopmental and neurodegenerative diseases. In addition to serving as a past president of the Society of Toxicology (2022-23), he served on numerous toxicology panels (U.S. EPA and CDC), been an expert reviewer for multiple federal agencies in the US and abroad, and is a member of the Neurotoxicology and Alcohol study section (NIH). He is a past recipient of the prestigious Society of Toxicology Merit Award (2010) and the Distinguished Neurotoxicologist Award (2020). He is a co-editor of the Elsevier series, Advancements in Neurotoxicology in addition to edited other Elsevier titles. He has published numerous articles and has served as an associate editor for multiple high impact factor journals.
Affiliations and expertise
Professor, Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY, USAWS
William Slikker Jr.
Dr. William Slikker, Jr. was the director of FDA’s National Center for Toxicological Research (NCTR) before his retirement. He received his Ph.D. in pharmacology and toxicology from the University of California at Davis. Dr. Slikker holds adjunct professorships in the Department of Pediatrics, as well as the Department of Pharmacology and Toxicology at the University of Arkansas for Medical Sciences. He has held committee chairmanships or elected offices in several scientific societies including the Teratology Society (serving as president) and the American Society for Pharmacology and Experimental Therapeutics (chair, Developmental Pharmacology Section and member, Program Committee). Dr. Slikker is also the co-founder and past president of the MidSouth Computational Biology and Bioinformatics Society. He is currently associate editor for NeuroToxicology and associate editor for the “Environmental Health” section of Experimental Biology and Medicine. He is the past president of The Academy of Toxicological Sciences and the Society of Toxicology. He is a recipient of the 2014 George H. Scott Memorial Award from The Toxicology Forum and was invited to present the Warkany Lecture at the 2015 annual meeting of the Teratology Society. In early 2019, the Academy of Toxicological Sciences selected Dr. Slikker to receive the prestigious Mildred S. Christian Career Achievement Award. The Society for Birth Defects Research and Prevention selected Dr. Slikker to be the recipient of the 2022 Edward W. Carney Distinguished Service Award.
Dr. Slikker has authored or co-authored over 380 publications in the areas of transplancentalpharmacokinetics, developmental neurotoxicology, neuroprotection, systems biology, and risk assessment. Dr. Slikker’s recent research has highlighted the concern for thousands of infants and toddlers who undergo longer-duration general anesthesia. He has performed research with his team and published over 25 peer-reviewed papers outlining the issue of brain-cell death and cognitive-function deficits in animal models that may result from several hours of anesthesia at a critical time of development. He has also, with the use of in vitro and in vivo techniques in rodents and nonhuman primates, defined possible mechanisms of toxicity and protective pathways to prevent the detrimental effects of general anesthesia. Through these and related scientific contributions, he has identified and characterized a host of minimally invasive biomarkers of neurotoxicity including the use of preclinical imaging (MRI, MicroPET/CT), genomic and lipidomic analysis, and modeling approaches to characterize and quantify adult and developmental neurotoxicity. He has also served on several national/international advisory panels for ILSI, HESI, CIIT, EPA, NIEHS, NAS, NIH and WHO.
Affiliations and expertise
National Center for Toxicological Research, Jefferson, US FDA, AR, USARead Neurotoxicity of Drugs of Abuse on ScienceDirect